Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 15/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 15/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.61 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 3/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.58 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16157002 | 1.00 | PDE3B (0.61) | PDE3BPDE3AGPR119PBRM1PDE4A | |
| SCHEMBL11268997 | 0.97 | PDE3B (0.62) | PDE3BPDE3AGPR119PBRM1PDE4A | |
| SCHEMBL10353457 | 0.91 | PDE3B (0.71) | PDE3BPDE3APBRM1PDE4APDE4B | |
| SCHEMBL11398120 | 0.87 | PBRM1 (0.54) | PDE3BPDE3AGPR119PBRM1PDE4A | |
| SCHEMBL10016799 | 0.85 | PDE3B (0.64) | PDE3BPDE3APBRM1PDE4APDE4B | |
| SCHEMBL22317993 | 0.85 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9687674 | 0.85 | PDE3B (0.64) | PDE3BPDE3APBRM1PDE4APDE4B | |
| SCHEMBL11633346 | 0.85 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL8342501 | 0.85 | PDE3B (0.64) | PDE3BPDE3APBRM1PDE4APDE4B | |
| SCHEMBL11630120 | 0.85 | GPR119 (0.70) | PDE3BPDE3AGPR119PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709388-A1 | INHIBITOR OF MEGAKARYOCYTE DIFFERENTIATION AND MATURATION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024232361-A1 | INHIBITOR OF MEGAKARYOCYTE DIFFERENTIATION AND MATURATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-14 | — | — | WO | disclosed |
| CN-108779076-B | 5-methyl-6-phenyl-4, 5-dihydro-2H-pyridazin-3-one derivatives | 大塚制药株式会社 | 2022-05-03 | — | — | CN | disclosed |
| CN-108779076-B | 5-methyl-6-phenyl-4, 5-dihydro-2H-pyridazin-3-one derivatives | 大塚制药株式会社 | 2022-05-03 | — | — | CN | disclosed |
| EP-3423440-B9 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS | OTSUKA PHARMA CO LTD (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3423440-B1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS | OTSUKA PHARMA CO LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| EP-3423440-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-09 | — | — | EP | disclosed |
| EP-0400519-A1 | 2-Hydroxy-n-propylamines, medicaments containing these compounds and method for preparing them | Dr. Karl Thomae GmbH (DE) | 1990-12-05 | — | — | EP | disclosed |
| US-4397854-A | INCREASE IN MYOCARDIAL CONTRACTILITY | WARNER-LAMBERT COMPANY (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | PDE3B 2704/4885PDE3A 2826/4885GPR119 2427/4885 |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | PDE3B 2704/4885PDE3A 2826/4885GPR119 2427/4885 |
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | PDE3B 2704/4885PDE3A 2826/4885GPR119 2427/4885 |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | PDE3B 2704/4885PDE3A 2826/4885GPR119 2427/4885 |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | VHL, H1-5, PRMT5 | PDE3B 2704/4885PDE3A 2826/4885GPR119 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.